Drug Pipeline

In the quest to adopt personalized medicine approaches, optimizing antiplatelet therapy based on platelet function testing is controversial.

Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.

Recent FDA action (through September 2012) related to, Lymphoseek, technetium Tc 99m tilmanocept, Tobramycin inhalation powder, Lixivaptan, CRTX 080, ALV003, AB103, Atox Bio

Recent FDA Approvals (through August 2012) related to (Innocutise, Genzyme, Sanofi, Pfizer, Amgen, Astellas Pharma US, Medivation, Gilead Sciences, Ironwood Pharmaceuticals, Forest, Reckitt Benckiser, Boehringer Ingelheim, Eli Lilly, Sicor Biotech UAB, Teva Corporation, Novartis)

New molecular entity: FDA approved the combination of sodium picosulfate (a stimulant laxative) and magnesium oxide and anhydrous citric acid (which form magnesium citrate, an osmotic laxative) (Prepopik, Ferring Pharmaceuticals) for cleansing of the colon as a preparation for colonoscopy in adults.

Rheumatoid arthritis is an autoimmune disorder in which the immune system targets synovial joints and causes mild-to-severe joint disease with extra-articular manifestations. This review discusses the current standards of care and details the data being collected on new agents.

Incretin-based therapies are now the most promising therapies for type 2 diabetes.

Recent FDA action (through August 2012) related to, ferric carboxymaltose injection, Injectafer, abiraterone acetate, Zytiga, cabozantinib, Exelixis, eltrombopag, Promacta, AEZS-130 oral ghrelin agonist, inhaled nitric oxide, GeNO LLC, gevokizumab, XOMA, calcipotriene cream, Dovonex, montelukast sodium, Singulair, lidocaine topical patch 5%, Lidoderm, filgrastim, Neupogen

New molecular entity: FDA approved Mirabegron (Myrbetriq, Astellas Pharma US) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Irritable bowel syndrome is functional gastrointestinal disorder that is expensive to treat and can impair quality of life. Current therapies are reviewed.

A look at the decision process that lead the Mayo Clinic to abandon the 80-mg dose of simvastatin

A recent study indicates that patients taking statins have a higher risk of developing cataracts.

Recent FDA Approvals (through August 2012) related to (CSL Limited, GlaxoSmithKline Biologicals, ID Biomedical Corp, MedImmune Vaccines, Novartis Vaccines and Diagnostics Limited, Sanofi Pasteur, Genentech, Talon Therapeutics, Amarin, Regeneron Pharmaceuticals, Horizon Pharma, Forest Pharmaceuticals, Onyx Pharmaceuticals, Novartis, Pfizer, Sagent Pharmaceuticals)

New molecular entity: FDA approved Lorcaserin (Belviq, Arena Pharmaceuticals GMBH), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index deemed obese and the presence of at least 1 weight-related comorbid condition.

A significant number of men who developed persistent sexual side effects from taking finasteride (Propecia and Proscar) also suffer from depressive symptoms and suicidal thoughts, according to a study published online in the Journal of Clinical Psychiatry.

Incretin-based therapies are now the most promising therapies for type 2 diabetes.

Teduglutide is a recombinant analog of human glucagon-like peptide-2 that is awaiting FDA approval for the treatment of short bowel syndrome (SBS) as a once-daily subcutaneous injection.

The passage of the FDA Safety and Innovation Act will support innovation, answer the current shortages, and even regulate mobile applications.

New molecular entity: FDA approved taliglucerase alfa (Elelyso, Pfizer), a recombinant active form of the glucocerebrosidase enzyme for long-term enzyme replacement therapy (ERT) for adults with type 1 Gaucher disease.

New formulation: FDA approved pancrelipase delayed-release capsules (Pertyze, Digestive Care, Inc.) for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions.

The Institute of Medicine reports that a number of issues are causing a number of barriers to successful HIV care in the United States.

Atrial fibrillation(AF) is the most common sustained cardiac arrhythmia and a potent risk factor for stroke. Here's a review of new oral anticoagulants for stroke prevention with AF.

The introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.

Screening for hepatitis-C may soon become a routine screening for Baby Boomers.

A new study seems to indicate that adding cetuximab to the standard therapy for resected stage 3 colon cancer provides no additional benefits.